Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.400 Biomarker group BEFREE Mutant pattern p53 IHC was observed in 63/63 (100%) serous carcinomas that were MMR proficient/POLE exonuclease domain wildtype. 31829441 2020
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.400 Biomarker group BEFREE Mutation type (diffuse or null) p53 staining was a powerful predictor of serous carcinomas. 31815745 2020
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.400 GeneticVariation group BEFREE FGFR3 and PIK3CA mutations were more frequent in low-grade noninvasive papillary carcinomas compared with high-grade noninvasive papillary carcinomas and carcinomas in situ (p < 0.0001), while the opposite was true for TP53 (p < 0.0001). 31028363 2019
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.400 GeneticVariation group BEFREE Recognition of this TP53 rearrangement pathway is essential to accurately identify prostatic carcinomas with loss of TP53 function. 31216325 2019
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.400 AlteredExpression group BEFREE Longstanding molecular observations implicate PTEN inactivation as a major driver of endometrioid carcinomas; TP53 inactivation as a major driver of most serous carcinomas, some high-grade endometrioid carcinomas, and many uterine carcinosarcomas; and inactivation of either gene as drivers of some clear cell carcinomas. 30332563 2019
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.400 GeneticVariation group BEFREE We have previously investigated mutations in the p53 tumor suppressor gene and the K-ras oncogene in lung carcinomas and in sputum samples from individuals exposed to smoky coal emissions in XWC. 29704996 2019
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.400 AlteredExpression group BEFREE Immunohistochemical stains, including, Napsin A and p504s can be used as ancillary diagnostic tools; p53 expression is aberrant in a minority of clear cell carcinomas. 30550483 2019
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.400 Biomarker group BEFREE As 100% (7/7) of serous EC and 3% (2/59) of the LGECs showed mutant-pattern p53 staining, histotype may serve as a surrogate for p53 assessment, such that only HGEC or ambiguous carcinomas should be routinely subjected to p53 immunostaining. 31569187 2019
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.400 Biomarker group BEFREE We performed a DNA- based multi-gene panel using ultra-deep sequencing analysis (including 14 genes with up to 452 amplicons in total; KRAS, NRAS, HRAS, BRAF, DDR2, ERBB2, KEAP1, NFE2L2, PIK3CA, PTEN, RHOA, BRCA1, BRCA2 and TP53) as well as an RNA-based gene fusion panel including ALK, BRAF, FGFR1, FGFR2, FGFR3, MET, NRG1, NTRK1, NTRK2, NTRK3, RET and ROS1 on eleven formalin fixed and paraffin embedded small bowel carcinomas. 30717682 2019
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.400 GeneticVariation group BEFREE We demonstrated that activation of RET is capable of inducing invasive pancreatic carcinomas in the background of the P53 inactivation mutation. 30515799 2019
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.400 GeneticVariation group BEFREE Carcinomas with POLE domain hotspot mutations are highly prognostically favorable; those with copy number alterations and TP53 mutations are highly aggressive; and microsatellite unstable and "copy number low" endometrioid are associated with intermediate prognoses. 31567131 2019
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.400 GeneticVariation group BEFREE There were significant immunophenotypic differences between adenosquamous carcinomas and pure invasive stratified mucin-producing carcinomas with regard to HPV (p < 0.0001), PAX8 (p = 0.038; more in adenosquamous carcinoma), p40 (p < 0.0001; more in adenosquamous carcinoma), p63 (p = 0.0018; more in adenosquamous carcinoma) and MUC6 (p  < 0.0001; less in adenosquamous carcinoma), HNF-1beta (p = 0.0023), vimentin (p = 0.0003), p53 (p = 0.0004), and CK7 (p = 0.0002) expression. 30258209 2019
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.400 AlteredExpression group BEFREE Most problems were related to Napsin A-negative clear cell, WT1-positive EC, and p53 IHC wild-type high-grade serous carcinomas. 29901523 2019
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.400 Biomarker group BEFREE To improve our understanding of the role of EMT in these tumors, we studied a series of 89 carcinomas including 14 undifferentiated/dedifferentiated endometrial carcinomas (UECs/DECs), 49 CSs (21 endometrial, 29 tubo-ovarian and peritoneal), 17 endometrioid carcinomas (grade 1-3), and 9 high-grade serous carcinomas of the uterus, using a panel of antibodies targeting known epithelial markers (Pan-Keratin AE1/AE3 and E-cadherin), mesenchymal markers (N-cadherin), EMT transcription factors (TFs) (ZEB1, ZEB2, TWIST1), PAX8, estrogen receptors (ER), progesterone receptors (PR), and the p53 protein. 30739164 2019
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.400 Biomarker group BEFREE TP63 (p63), a member of the tumor suppressor TP53 (p53) gene family, is essential for ectodermal tissue development and suppresses malignant progression of carcinomas. 30986748 2019
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.400 GeneticVariation group BEFREE Analysis of Telomere Lengths in p53 Signatures and Incidental Serous Tubal Intraepithelial Carcinomas Without Concurrent Ovarian Cancer. 31107721 2019
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.400 AlteredExpression group BEFREE BART5-3p is the first EBV-microRNA to be identified as inhibiting p53 expression and function, which suggests a novel mechanism underlying the strategies employed by EBV to maintain latent infection and promote the development of EBV-associated carcinomas.<b>IMPORTANCE</b> EBV encodes 44 mature microRNAs, which have been proven to promote EBV-associated diseases by targeting host genes and self-viral genes. 30209170 2018
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.400 GeneticVariation group BEFREE The distal Fallopian tube is a site of origin for many 'ovarian' high-grade serous carcinomas (HGSCs) with intraepithelial carcinomas (STICs) that share identical TP53 mutations with metastatic tumors. 30043522 2018
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.400 AlteredExpression group BEFREE In summary, these findings identify aggressive clinicopathologic features of polyoma T-antigen-expressing carcinomas, document BK as the strain involved, and associate BK viral integration with T-antigen expression and p53 aberrancy. 29765141 2018
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.400 GeneticVariation group BEFREE Probably, these carcinomas might acquire undifferentiated phenotype through mutations in TP53 and POLE. 29133142 2018
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.400 GeneticVariation group BEFREE Alterations of p53 and Rb Pathways Are Associated with High Proliferation in Bladder Urothelial Carcinomas. 29970521 2018
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.400 GeneticVariation group BEFREE However, the data support a tumor suppressor role for DAXX as low-dose ionizing radiation produced a higher proportion of carcinomas in Daxx heterozygous mice than wild-type controls.<b>Implications:</b> While DAXX has important <i>in vivo</i> functions, they are independent of an inhibitory role on the p53 tumor suppressor pathway.<i></i>. 29903771 2018
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.400 GeneticVariation group BEFREE Carcinomas with polymerase E (POLE) exonuclease domain hotspot mutations are highly prognostically favourable; those with copy-number alterations and TP53 mutations are highly aggressive; and microsatellite unstable and 'copy-number low' endometrioid carcinomas are associated with intermediate prognoses. 29246451 2018
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.400 GeneticVariation group BEFREE Extrauterine high-grade serous carcinomas with bilateral adnexal involvement as the only two disease sites are clonal based on tp53 sequencing results: implications for biology, classification, and staging. 29148539 2018
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.400 GeneticVariation group BEFREE Most of the genes that are commonly associated with colon cancer, including APC, TP53, and KRAS, were all classified as being early driver genes being mutated in both adenomas and carcinomas. 29575536 2018